Enzymes

The NNMT Fluorogenic Assay Kit is designed to measure NNMT (Nicotinamide N-methyltransferase) activity for screening and profiling applications. The assay kit comes in a convenient 96-well format, with enough recombinant NNMT, substrate, cofactor, and assay buffer for 100 enzyme reactions.

Please note this product may be subject to fees, we invite you to contact your local office. The TRα-GAL4 Luciferase Reporter HEK293 Cell Line is a HEK293 cell line expressing firefly luciferase under the control of the GAL4 upstream activation sequence (UAS) with constitutive expression of human thyroid receptor α ligand binding domain fused to the DNA binding domain (DBD) of GAL4 (GAL4 DBD). This system allows specific detection of thyroid hormone-induced activation of the thyroid receptor α with low cross-reactivity from other nuclear receptors. This cell line has been validated by stimulation with triiodothyronine (T-3).

Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) of interest in the treatment of obesity.

Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) of interest in the treatment of obesity.

Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) of interest in the treatment of obesity.

Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting GLP-1 ( glucagon-like peptide-1) receptor agonist that promotes insluin secretion, and of potential use in the treatment of MASH.

Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting GLP-1 ( glucagon-like peptide-1) receptor agonist that promotes insluin secretion, and of potential use in the treatment of MASH.

Lixisenatide is a GLP-1 (glucagon-like peptide-1) receptor agonist used in the treatment of type 2 diabetes (T2D). Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways.

Lixisenatide is a GLP-1 (glucagon-like peptide-1) receptor agonist used in the treatment of type 2 diabetes (T2D). Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways.